HY-P9967-1mg
|
MedChemexpress LLC
|
Aducanumab [CAS 1384260-65-4]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P9967-10mg
|
MedChemexpress LLC
|
Aducanumab [CAS 1384260-65-4]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P9967-5mg
|
MedChemexpress LLC
|
Aducanumab [CAS 1384260-65-4]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99185-1mg
|
MedChemexpress LLC
|
Bapineuzumab [CAS 648895-38-9]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99185-10mg
|
MedChemexpress LLC
|
Bapineuzumab [CAS 648895-38-9]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99185-5mg
|
MedChemexpress LLC
|
Bapineuzumab [CAS 648895-38-9]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99356-1mg
|
MedChemexpress LLC
|
Cinpanemab [CAS 2094516-02-4]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99356-10mg
|
MedChemexpress LLC
|
Cinpanemab [CAS 2094516-02-4]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99356-5mg
|
MedChemexpress LLC
|
Cinpanemab [CAS 2094516-02-4]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99859-1mg
|
MedChemexpress LLC
|
Donanemab [CAS 1931944-80-7]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99859-10mg
|
MedChemexpress LLC
|
Donanemab [CAS 1931944-80-7]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99859-5mg
|
MedChemexpress LLC
|
Donanemab [CAS 1931944-80-7]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99022-1mg
|
MedChemexpress LLC
|
Gantenerumab [CAS 1043556-46-2]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99022-10mg
|
MedChemexpress LLC
|
Gantenerumab [CAS 1043556-46-2]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99022-5mg
|
MedChemexpress LLC
|
Gantenerumab [CAS 1043556-46-2]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99648-1mg
|
MedChemexpress LLC
|
Gosuranemab [CAS 1788032-39-2]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99648-10mg
|
MedChemexpress LLC
|
Gosuranemab [CAS 1788032-39-2]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99648-5mg
|
MedChemexpress LLC
|
Gosuranemab [CAS 1788032-39-2]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99216-1mg
|
MedChemexpress LLC
|
Ponezumab [CAS 1178862-65-1]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99216-5mg
|
MedChemexpress LLC
|
Ponezumab [CAS 1178862-65-1]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99399-1mg
|
MedChemexpress LLC
|
Semorinemab [CAS 2159141-27-0]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99399-10mg
|
MedChemexpress LLC
|
Semorinemab [CAS 2159141-27-0]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99399-5mg
|
MedChemexpress LLC
|
Semorinemab [CAS 2159141-27-0]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99317-1mg
|
MedChemexpress LLC
|
Solanezumab [CAS 955085-14-0]
|
|
Neuroscience-Neurodegeneration
|
|
HY-P99317-10mg
|
MedChemexpress LLC
|
Solanezumab [CAS 955085-14-0]
|
|
Neuroscience-Neurodegeneration
|
|